Skip to main content
. Author manuscript; available in PMC: 2008 Oct 2.
Published in final edited form as: Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77–85. doi: 10.1002/ajmg.c.30087

Fig. 4. Plasma acylcarnitine profiles from a normal control (top) and a patient with CACT deficiency.

Fig. 4

The acylcarnitine profiles were obtained at time of diagnosis (7 days of age) and after therapy with medium chain triglycerides and carnitine supplements (1 and 5.5 months of age). Note the progressive decline in C16 and C18:1 and the increase in medium-chain acylcarnitines (C6—C10) reflecting treatment with medium-chain triglycerides (from [Iacobazzi et al., 2004b].